EFNS偏头痛药物治疗指南 EFNS特别工作组的报告

被引：13

作者：

SEvers ^{[1
]}

Jfra ^{[2
]}

AFrese ^{[1
]}

PJGoadsby ^{[3
]}

MLinde ^{[4
]}

AMay ^{[5
]}

PSSndor ^{[6
]}

张现伟 ^{[7
]}

张敏 ^{[7
]}

吴宣富 ^{[7
]}

机构：

[1] Department of Neurology,University of Münster,Münster,Germany

[2] National Institute of Neurosurgery,Budapest,Hungary

[3] Headache Group,Institute of Neurology,The National Hospital for Neurology and Neurosurgery,London,UK

[4] Cephalea Pain Center,Lkarhnset Sdra vgen,Gothenburg,Gothenburg,Sweden

[5] Department of Neurology,University of Hamburg,Hamburg,Germany

[6] Department of Neurology,University of Zurich,Zurich,Switzerland

[7] 广州中医药大学第一附属医院神经内科

来源：

国际脑血管病杂志 | 2007年 / 15卷 / 12期

关键词：

指南; 头痛; 偏头痛; 预防; 曲坦类药物;

D O I：

暂无

中图分类号：

R747.2 [偏头痛];

学科分类号：

1002 ;

摘要：

偏头痛是最常见的功能障碍性神经疾病之一,会对患者的生活质量造成严重影响。为了在文献检索和专家组共识基础上对不同类型偏头痛综合征的各种药物治疗方案提供循证或专家推荐,我们从现有的所有医学参考文献系统中筛选出关于有先兆型或无先兆型偏头痛以及偏头痛样综合征等各种类型临床资料进行分析。根据欧洲神经病学学会联盟(European Federation of Neurological Societies.EFNS)制定的推荐意见分级方案对这些研究结果进行评价从而确定A级、B级或C级推荐和良好的临床实践要点。对于偏头痛急性发作期的治疗,推荐口服非甾体消炎药(NSAID)和曲坦类药物。用药方案应遵循分层治疗的观念。在服用NSAID和曲坦类药物之前,推荐口服甲氧氯普胺或多潘立酮。极重度发作的首选药物为静脉注射乙酰水杨酸或皮下注射舒马曲坦。偏头痛持续状态或许可用类固醇治疗。对于偏头痛的预防性治疗,β-受体阻断药(普萘洛尔和美托洛尔)、氟桂利嗪、丙戊酸和托吡酯可作为首选用药,其次可选择阿米替林、萘普生、蜂斗菜烯碱和比索洛尔。

引用

页码：881 / 890

页数：10

共 39 条

[1]

Efficacy of coenzyme Q10 in migraine prophylaxis: A randomized controlled trial[J] . P S. Sándor,L Di Clemente,G Coppola,U Saenger,A Fumal,D Magis,L Seidel,R M. Agosti,J Schoenen.Neurology . 2005 (4)

[2]

Practice Parameter: Pharmacological treatment of migraine headache in children and adolescents: Report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society[J] . D Lewis,S Ashwal,A Hershey,D Hirtz,M Yonker,S Silberstein.Neurology . 2004 (12)

[3] Petasites hybridus root (butterbur) is an effective preventive treatment for migraine [J].

Lipton, RB ;

Göbel, H ;

Einhäupl, KM ;

Wilks, K ;

Mauskop, A .

NEUROLOGY, 2004, 63 (12) :2240-2244

[4]

Topiramate in migraine prophylaxis: a randomised double-blind versus placebo study[J] . D. Mei,A. Capuano,C. Vollono,M. Evangelista,D. Ferraro,P. Tonali,G. Trapani.Neurological Sciences . 2004 (5)

[5] No effect of eletriptan administration during the aura phase of migraine [J].

Olesen, J ;

Diener, HC ;

Schoenen, J ;

Hettiarachchi, J .

EUROPEAN JOURNAL OF NEUROLOGY, 2004, 11 (10) :671-677

[6] A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine [J].

Silberstein, SD ;

Elkind, AH ;

Schreiber, C ;

Keywood, C .

NEUROLOGY, 2004, 63 (02) :261-269

[7]

Topiramate in migraine prophylaxis[J] . Hans-Christoph Diener,P. Tfelt-Hansen,C. Dahl?f,M. J. A. Láinez,G. Sandrini,Sh.-J. Wang,W. Neto,U. Vijapurkar,A. Doyle,D. Jacobs.Journal of Neurology . 2004 (8)

[8]

Triptans in migraine: The risks of stroke, cardiovascular disease, and death in practice[J] . Gillian C. Hall,Martin M. Brown,Jingping Mo,Kenneth D. MacRae.Neurology . 2004 (4)

[9]

Efficacy and tolerability of acetazolamide in migraine prophylaxis: A randomised placebo-controlled trial[J] . K. Vahedi,P. Taupin,R. Djomby,M. El-Amrani,G. Lutz,V. Filipetti,P. Landais,H. Massiou,M. G. Bousser.Journal of Neurology . 2002 (2)

[10] A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis [J].

Freitag, FG ;

Collins, SD ;

Carlson, HA ;

Goldstein, J ;

Saper, J ;

Silberstein, S ;

Mathew, N ;

Winner, PK ;

Deaton, R ;

Sommerville, K .

NEUROLOGY, 2002, 58 (11) :1652-1659

← 1 2 3 4 →